162 related articles for article (PubMed ID: 15500142)
1. [Secondary nephrotic syndrome due to cardiovascular disease].
Hirayama T; Takahashi F; Kikuchi K
Nihon Rinsho; 2004 Oct; 62(10):1930-4. PubMed ID: 15500142
[TBL] [Abstract][Full Text] [Related]
2. Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation.
Freiberger V; Amann K; Heemann U; Frank H
Transpl Int; 2009 Nov; 22(11):1110-3. PubMed ID: 19497068
[TBL] [Abstract][Full Text] [Related]
3. Candesartan for cardiovascular prevention in Japanese hypertensive patients with coronary heart disease.
Staessen JA; Richart T; Birkenhäger WH
Eur Heart J; 2009 May; 30(10):1164-6. PubMed ID: 19363059
[No Abstract] [Full Text] [Related]
4. Renovascular hypertension: a unique cause of unilateral focal segmental glomerulosclerosis.
Alchi B; Shirasaki A; Narita I; Nishi S; Ueno M; Saeki T; Miyamura S; Gejyo F
Hypertens Res; 2006 Mar; 29(3):203-7. PubMed ID: 16755156
[TBL] [Abstract][Full Text] [Related]
5. Effects of captopril on both hypertension and proteinuria. Report of a case of renovascular hypertension associated with nephrotic syndrome.
Takeda R; Morimoto S; Uchida K; Kigoshi T; Sumitani T; Matsubara F
Arch Intern Med; 1980 Nov; 140(11):1531-3. PubMed ID: 7002084
[No Abstract] [Full Text] [Related]
6. [A case of renovascular hypertension with nephrotic syndrome].
Fukushima T; Saiki T; Jyo Y; Sasaki T; Satoh T; Nomura S; Hirano H; Osawa G
Nihon Jinzo Gakkai Shi; 1995 Oct; 37(10):595-9. PubMed ID: 7474513
[TBL] [Abstract][Full Text] [Related]
7. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.
Saruta T; Hayashi K; Ogihara T; Nakao K; Fukui T; Fukiyama K;
Hypertens Res; 2009 Jun; 32(6):505-12. PubMed ID: 19390535
[TBL] [Abstract][Full Text] [Related]
8. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
Yamaguchi J; Hagiwara N; Ogawa H; Koyanagi R; Kasanuki H; Takagi A; Mori F; Nagashima M; Yagi M;
Am J Cardiol; 2010 Sep; 106(6):819-24. PubMed ID: 20816122
[TBL] [Abstract][Full Text] [Related]
9. A case of renovascular hypertension with the nephrotic syndrome.
Fujioka S; Sasakawa O; Suzuki R; Nogi O; Tsumura K; Komori T; Morii H
Jpn J Med; 1986 Aug; 25(3):317-20. PubMed ID: 3534395
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular protection with candesartan in patients with metabolic disorders.
Barrios V; Escobar C; Calderon A
Hypertens Res; 2010 Dec; 33(12):1312-3. PubMed ID: 20664548
[No Abstract] [Full Text] [Related]
11. [Prevension of hypertension by angiotensin receptor blockers in human--TROPHY study].
Ohya Y; Inoue T
Nihon Rinsho; 2008 Aug; 66(8):1596-600. PubMed ID: 18700563
[TBL] [Abstract][Full Text] [Related]
12. Multiple manifestations of renovascular hypertension.
Sekkarie M; Olutade B; Peterson P
Am J Kidney Dis; 1994 Jun; 23(6):866-8. PubMed ID: 8203370
[TBL] [Abstract][Full Text] [Related]
13. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
Willemsen JM; Rabelink TJ; Boer P; Gaillard CA
J Hum Hypertens; 2004 Dec; 18(12):857-63. PubMed ID: 15361886
[TBL] [Abstract][Full Text] [Related]
14. Candesartan: widening indications for this angiotensin II receptor blocker?
Mendis B; Page SR
Expert Opin Pharmacother; 2009 Aug; 10(12):1995-2007. PubMed ID: 19563275
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function.
Shiga T; Kasanuki H; Hagiwara N; Sumiyoshi T; Honda T; Haze K; Takagi A; Kawana M; Origasa H; Ogawa H;
Blood Press; 2010 Dec; 19(6):359-65. PubMed ID: 20491606
[TBL] [Abstract][Full Text] [Related]
16. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial.
Cooper CJ; Murphy TP; Matsumoto A; Steffes M; Cohen DJ; Jaff M; Kuntz R; Jamerson K; Reid D; Rosenfield K; Rundback J; D'Agostino R; Henrich W; Dworkin L
Am Heart J; 2006 Jul; 152(1):59-66. PubMed ID: 16824832
[TBL] [Abstract][Full Text] [Related]
17. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
Fogari R; Zoppi A; Mugellini A; Maffioli P; Lazzari P; Derosa G
Hypertens Res; 2011 Dec; 34(12):1321-6. PubMed ID: 21814211
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex).
Ueshima K; Oba K; Yasuno S; Fujimoto A; Sato T; Fukiyama K; Azuma J; Ogihara T; Saruta T; Nakao K;
Contemp Clin Trials; 2009 Jan; 30(1):97-101. PubMed ID: 18824134
[TBL] [Abstract][Full Text] [Related]
19. Candesartan reduces cardiovascular events in patients on chronic haemodialysis.
Almirall J; Valenzuela MP; Lopez T
Nephrol Dial Transplant; 2007 Jan; 22(1):281; author reply 281-2. PubMed ID: 17085461
[No Abstract] [Full Text] [Related]
20. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).
Kasanuki H; Hagiwara N; Hosoda S; Sumiyoshi T; Honda T; Haze K; Nagashima M; Yamaguchi J; Origasa H; Urashima M; Ogawa H;
Eur Heart J; 2009 May; 30(10):1203-12. PubMed ID: 19346521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
